Nii MRK kui SGP on oma tulemused edastanud. enamik farmasid on seni tulnud kergelt paremate tulemustega. Tugev sektor ja tugevasti üles ostetud sektor. Väike kokkuvõte:
Including the charge Merck (MRK) reported third-quarter earnings of $940.6 million, or 43 cents a share, down from a year-ago profit of $1.42 billion, or 65 cents a share.
Schering-Plough (SGP) reported third-quarter net income of $309 million, up from a year-ago profit of $65 million. After the payment of preferred dividends, the company earned $287 million, or 19 cents a share, in the three months ended Sept. 30, up from a year-ago equivalent profit of $43 million, or 3 cents a share.
After tax adjustments, Pfizer (PFE) third-quarter net income more than doubled to $3.36 billion, or 46 cents a share, from $1.59 billion, or 22 cents a share. From continuing operations, Pfizer said it earned 44 cents a share.
Novartis AG reported third-quarter net profits rose 12 percent to $1.87 billion, up from $1.67 billion for the same period last year.
Eli Lilly and Co (LLY). Net income grew to $873.6 million, or 80 cents per share, from $794.4 million, or 73 cents per share, a year ago.
Wyeth's (WYE) quarterly profit grew to $1.16 billion, or 85 cents per share, from $869.9 million, or 64 cents per share.
Novartis (NVS) net profit rose 12% to $1.87 billion from $1.67 billion a year earlier.
Indian generic-drug maker Ranbaxy net profit after taxes and minority interests jumped to 1.39 billion rupees ($30.7 million), from 184 million rupees a year earlier. Revenue rose 27% to 16.27 billion rupees.